MKI67 and ovarian carcinoma: According to our results, MKI67 expression was increased in bladder cancer, CNS and brain cancers, breast cancer (BC), head and neck cancer (HNC), colorectal cancer (CRC), oesophageal cancer (EC), cervical cancer, gastric cancer (GC), liver cancer, lung cancer (LC), lymphoma, ovarian cancer, pancreatic cancer, and sarcoma compared with noncarcinoma samples (Fig. 1a).